Showing 3161-3170 of 3946 results for "".
- Incyte Scores Vitiligo Nod for Opzelura Cream in Europehttps://practicaldermatology.com/news/incyte-scores-nod-for-opzelura-cream-for-vitiligo-in-europe/2461674/The European Commission (EC) has granted a marketing authorization for Opzelura (ruxolitinib) cream15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. The selective JAK1/JAK2 inhibi
- Skin Cancer Foundation Hits the Road: Destination Healthy Skin Program Kicks Off on May 6, 2023https://practicaldermatology.com/news/skin-cancer-foundation-hits-the-road-destination-healthy-skin-program-kicks-off-on-may-6-2023/2461669/The Skin Cancer Foundation will launch its annual mobile education and screening program, Destination Healthy Skin, on Saturday, May 6, in Greenwich, Connecticut. The program educates the public about the importance of skin cancer early detection and effective sun p
- ASLMS News: BTL Unveils EXIONhttps://practicaldermatology.com/news/aslms-news-btl-unveils-exion/2461661/Just in time for their 30th anniversary, BTL is launching EXION, a multiplatform device featuring micro-needling RF, a non-invasive face and body applicator for skin laxity, and the EMFEMME 360 applicator for intimate health. EXION can also be combined with EMFACE to treat bot
- Millennials, Gen Xers Not Well-Schooled on Skin Cancer Preventionhttps://practicaldermatology.com/news/millennials-gen-xers-not-well-schooled-on-skin-cancer-prevention/2461648/Millennials and Gen Xers are racked with sun regrets, a new survey shows. Just 19% of millennials and Gen Xers wear sunscreen all year, 35% used a tanning bed, and 46% regretted how long they stayed out in the sun when they were younger. This is why
- Phase 3 Data Evaluating Almirall’s Lebrikizumab in Moderate-to-Severe Atopic Dermatitis Publishedhttps://practicaldermatology.com/news/phase-3-data-evaluating-almiralls-lebrikizumab-in-moderate-to-severe-atopic-dermatitis-published/2461640/Almirall announced the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. ADvocate1 and ADvocate2 are two identical 52-week randomized, double-blind, plac
- Analysis Reveals How Incurable Skin Cancer Resists Treatmenthttps://practicaldermatology.com/news/research-autopsies-reveals-how-incurable-skin-cancer-resists-treatment/2461637/A new analysis published in the journal Cancer Discovery reveals how some skin cancers stop responding to treatment at the end of l
- Phase 3 Studies Show Lebrikizumab Effective in Patients With Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/phase-3-studies-show-lebrikizumab-effective-in-patients-with-moderate-to-severe-atopic-dermatitis/2461630/After 16 weeks of treatment, lebrikizumab (Almirall) was effective in adolescents and adults with moderate-to-severe atopic dermatitis, according to two Phase 3 studies. The research was published in the New England Journal of
- New Way to Measure Skin Barrier Function Identifiedhttps://practicaldermatology.com/news/new-way-to-measure-skin-barrier-function-identified/2461628/Scientists in Japan have devised a new way to measure skin barrier function. Most methods indirectly calculate skin barrier function using a proxy measure called transepidermal water loss (TEWL), but the dependance on a heavily controlled environment is one of the primary limitations of this
- LEO Pharma Adds to Global Leadership Teamhttps://practicaldermatology.com/news/leo-pharma-adds-to-global-leadership-team/2461607/Dr. Jacob Pontoppidan Thyssen is the new Executive Vice President and Chief Scientific Officer for LEO Pharma’s Research and Early Development arm. The company announced that a significant shift in R&D to a research model in early 2023. The change aims to drive the early-stage
- PCA Skin Rings in the Fourth Annual National Peel Dayhttps://practicaldermatology.com/news/pca-skin-rings-in-the-fourth-annual-national-peel-day/2461598/March 10, 2023 is the fourth annual National Peel Day, created by PCA SKIN. "National Peel Day was established in 2020 to drive awareness, increase education, and demystify misconceptions around the non-invasive treatment,” says Joanna Zucker, CEO CP Skin Health Group US